Hanmi Pharm Overview
- Year Founded
-
1973
- Status
-
Public
- Employees
-
2,400
- Stock Symbol
-
128940
- Investments
-
7
- Share Price
-
$336.68
- (As of Friday Closing)
Hanmi Pharm General Information
Description
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.
Contact Information
Website
www.hanmipharm.comCorporate Office
- 14, Wiryeseong-daero
- Songpa
- Seoul, Gyeonggi 05545
- South Korea
Corporate Office
- 14, Wiryeseong-daero
- Songpa
- Seoul, Gyeonggi 05545
- South Korea
Hanmi Pharm Stock Performance
As of 20-Nov-2026, Hanmi Pharm’s stock price is $336.68. Its current market cap is $4.28B with 12.7M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $336.68 | $316.72 | $207.54 - $448.00 | $4.28B | 12.7M | 152K | $10.21 |
Hanmi Pharm Financials Summary
As of 30-Sep-2026, Hanmi Pharm has a trailing 12-month revenue of $1.14B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 4,829,031 | 4,244,969 | 2,730,571 | 3,805,905 |
| Revenue | 1,144,557 | 1,087,408 | 1,096,058 | 1,140,302 |
| EBITDA | 240,678 | 226,266 | 210,558 | 241,930 |
| Net Income | 129,594 | 119,141 | 88,912 | 111,845 |
| Total Assets | 1,624,287 | 1,484,433 | 1,371,949 | 1,473,344 |
| Total Debt | 284,755 | 301,534 | 337,201 | 444,538 |
Hanmi Pharm Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hanmi Pharm Comparisons
Industry
Financing
Details
Hanmi Pharm Competitors (14)
One of Hanmi Pharm’s 14 competitors is Yuhan, a Corporation company based in Seoul, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Yuhan | Corporation | Seoul, South Korea | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| GSK | Corporation | London, United Kingdom | ||||
| Celltrion | Formerly VC-backed | Incheon, South Korea |
Hanmi Pharm Patents
Hanmi Pharm Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026235366-A1 | Messenger ribonucleic acid encoding analogs of p53 protein, and medical uses thereof | Pending | 09-May-2025 | ||
| WO-2026212360-A1 | Modified sting protein, nucleic acid encoding same, and use thereof | Pending | 02-Apr-2025 | ||
| WO-2026142281-A1 | Therapeutic agent for gastroesophageal reflux disease with improved dosing convenience using water-insoluble polymer | Pending | 23-Dec-2024 | ||
| WO-2026135347-A1 | Ep300 protein degrader and use thereof | Pending | 20-Dec-2024 | ||
| WO-2026135298-A1 | Liposome composition for oral administration comprising glp-1 analog and method for preparing same | Pending | 20-Dec-2024 | A61K9/127 |
Hanmi Pharm Signals
Hanmi Pharm Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hanmi Pharm Investments & Acquisitions (7)
Hanmi Pharm’s most recent deal was a Merger/Acquisition with Aptose Biosciences for . The deal was made on 30-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Aptose Biosciences | 30-Jun-2026 | Merger/Acquisition | Drug Discovery | ||
| Aptose Biosciences | 31-Jan-2024 | PIPE | Drug Discovery | ||
| Darmiyan | 10-Apr-2020 | Seed Round | Decision/Risk Analysis | ||
| Tomocube | 29-Mar-2016 | Early Stage VC | Diagnostic Equipment | ||
| Allegro Ophthalmics | 26-Jan-2015 | Later Stage VC | Drug Discovery |
Hanmi Pharm ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
30.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Hanmi Pharm Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Aptose Biosciences | Toronto, Canada | 1986 | |
| Hanmi Pharm (Global Rights to HM17321) | Seoul, South Korea |
Hanmi Pharm FAQs
-
When was Hanmi Pharm founded?
Hanmi Pharm was founded in 1973.
-
Where is Hanmi Pharm headquartered?
Hanmi Pharm is headquartered in Seoul, South Korea.
-
What is the size of Hanmi Pharm?
Hanmi Pharm has 2,400 total employees.
-
What industry is Hanmi Pharm in?
Hanmi Pharm’s primary industry is Biotechnology.
-
Is Hanmi Pharm a private or public company?
Hanmi Pharm is a Public company.
-
What is Hanmi Pharm’s stock symbol?
The ticker symbol for Hanmi Pharm is 128940.
-
What is the current stock price of Hanmi Pharm?
As of 20-Nov-2026 the stock price of Hanmi Pharm is $336.68.
-
What is the current market cap of Hanmi Pharm?
The current market capitalization of Hanmi Pharm is $4.28B.
-
What is Hanmi Pharm’s current revenue?
The trailing twelve month revenue for Hanmi Pharm is $1.14B.
-
Who are Hanmi Pharm’s competitors?
Yuhan, Genentech, Merck & Co., GSK, and Celltrion are some of the 14 competitors of Hanmi Pharm.
-
What is Hanmi Pharm’s annual earnings per share (EPS)?
Hanmi Pharm’s EPS for 12 months was $10.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process